Back-to-back gene therapy approvals give Bluebird shot at survival
Bio Pharma Dive
SEPTEMBER 19, 2022
The FDA's clearances of Zynteglo and Skysona are a boost to Bluebird, and could help lift the research field after a series of setbacks. But selling the high-priced therapies will be a challenge.
Let's personalize your content